[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcAa-D1Y_9Pni6bDaIfYDVuUy1W-g0xSkt-e7NlVC3E0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Loyola University",[4,6],"Loyola University Chicago",138,false,21,7,24051,20,64,[15,17,20,23,25,28,30,33],{"name":16,"count":10},"Obesity",{"name":18,"count":19},"Diabetes",6,{"name":21,"count":22},"Overactive Bladder",5,{"name":24,"count":22},"Ovarian Cancer",{"name":26,"count":27},"Pelvic Organ Prolapse",4,{"name":29,"count":27},"Pain",{"name":31,"count":32},"Pelvic Girdle Pain",3,{"name":34,"count":32},"Depression",[36,41,46,51,56,61,66,71,76,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04214886","CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies","2022-08-11","Fludarabine",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05554068","Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients","2025-03-07","Shingrix",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05985629","IPACK on Early Pain Scores After ACL Reconstruction","2025-08-03","IPACK",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05557279","Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks","2025-12-01","500 mg NDS-446",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06619301","RCT Glargine vs NPH for Treatment of DM in Pregnancy","2026-04-01","Insulin glargine",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05824832","Buprenorphine, Clonidine, and Dexamethasone on Duration of Brachial Plexus Blocks for Upper Extremity Surgery","2026-06-30","Interscalene block with the addition of buprenorphine, clonidine, dexamethasone",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06284473","Ketamine as a Supplement to Local Anesthesia for Minor Procedures","2028-05-31","Ketamine",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT02870244","Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes","2028-09","Escalating Doses",{"nctId":77,"briefTitle":78,"date":74,"intervention":79},"NCT01586403","Transfer of Genetically Engineered Lymphocytes in Melanoma Patients","Dose 1",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT05983276","Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer","2030-08-28","Decitabine",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,142,164,182,202,225,250,268,315,333,351,369,391,452,470,488,509,532,550,568,586,620,650,675,699,725,750,775,801,819,845,863,889,914,932,956,984,1002,1026,1044,1073,1091,1109,1138,1162,1189,1207,1233,1257,1283,1306,1331,1356,1383,1410,1437,1466,1484,1509,1534,1559,1584,1602,1620,1638,1684,1708,1732,1750,1774,1792,1810,1828,1846,1864,1887,1909,1927,1952,1970,1994,2017,2044,2062,2080,2103,2121,2139,2161,2179,2202,2229,2254,2277,2304,2322,2346,2370,2392,2416,2440,2458],{"intervention":70,"totalTrials":32,"cells":94},{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":140},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":139,"soonestReadout":69},[106,117,127],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"NCT03714620","Sub-dissociative Dose Ketamine Dosing Study","COMPLETED",[90],"2019-09-17","2018-10-15",98,[115],"Acute Pain",[70],{"nctId":67,"briefTitle":68,"status":118,"phases":119,"primaryCompletion":69,"completion":69,"start":120,"enrollment":121,"conditions":122,"interventions":126},"RECRUITING",[90],"2022-05-25",108,[123,124,125],"Pain, Procedural","Minor Laceration","Abscess",[70],{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},"NCT03049930","Intraoperative Low-dose Ketamine Infusion as the Main Analgesic in Burn Patients","UNKNOWN",[90],"2020-08","2018-02-27",46,[136],"Burns",[70,138],"Sodium chloride",1,{"trials":141,"activeCount":97},[],{"intervention":65,"totalTrials":139,"cells":143},{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":162},{"trials":145,"activeCount":97},[],{"trials":147,"activeCount":97},[],{"trials":149,"activeCount":97},[],{"trials":151,"activeCount":97},[],{"trials":153,"activeCount":139,"soonestReadout":64},[154],{"nctId":62,"briefTitle":63,"status":118,"phases":155,"primaryCompletion":64,"completion":64,"start":156,"enrollment":157,"conditions":158,"interventions":160},[90],"2023-02-28",120,[159],"Pain, Postoperative",[65,161],"Interscalene block with buprenorphine alone",{"trials":163,"activeCount":97},[],{"intervention":161,"totalTrials":139,"cells":165},{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":174,"NA":180},{"trials":167,"activeCount":97},[],{"trials":169,"activeCount":97},[],{"trials":171,"activeCount":97},[],{"trials":173,"activeCount":97},[],{"trials":175,"activeCount":139,"soonestReadout":64},[176],{"nctId":62,"briefTitle":63,"status":118,"phases":177,"primaryCompletion":64,"completion":64,"start":156,"enrollment":157,"conditions":178,"interventions":179},[90],[159],[65,161],{"trials":181,"activeCount":97},[],{"intervention":55,"totalTrials":139,"cells":183},{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":192,"NA":200},{"trials":185,"activeCount":97},[],{"trials":187,"activeCount":97},[],{"trials":189,"activeCount":97},[],{"trials":191,"activeCount":97},[],{"trials":193,"activeCount":139,"soonestReadout":54},[194],{"nctId":52,"briefTitle":53,"status":118,"phases":195,"primaryCompletion":54,"completion":54,"start":196,"enrollment":197,"conditions":198,"interventions":199},[90],"2023-01-01",40,[21],[55],{"trials":201,"activeCount":97},[],{"intervention":50,"totalTrials":139,"cells":203},{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":212,"NA":223},{"trials":205,"activeCount":97},[],{"trials":207,"activeCount":97},[],{"trials":209,"activeCount":97},[],{"trials":211,"activeCount":97},[],{"trials":213,"activeCount":139,"soonestReadout":49},[214],{"nctId":47,"briefTitle":48,"status":118,"phases":215,"primaryCompletion":49,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":222},[90],"2026-08-03","2023-08-03",78,[159,220,221],"Anterior Cruciate Ligament Injuries","Analgesics, Opioid",[50],{"trials":224,"activeCount":97},[],{"intervention":60,"totalTrials":139,"cells":226},{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":246,"NA":248},{"trials":228,"activeCount":97},[],{"trials":230,"activeCount":97},[],{"trials":232,"activeCount":97},[],{"trials":234,"activeCount":139,"soonestReadout":59},[235],{"nctId":57,"briefTitle":58,"status":118,"phases":236,"primaryCompletion":59,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":244},[89],"2027-01-01","2024-04-01",160,[241,242,243],"Diabetes Mellitus in Pregnancy","Type 2 Diabetes Mellitus (T2DM)","Gestational Diabetes Mellitus, Class A2",[60,245],"insulin NPH",{"trials":247,"activeCount":97},[],{"trials":249,"activeCount":97},[],{"intervention":245,"totalTrials":139,"cells":251},{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":258,"PHASE4":264,"NA":266},{"trials":253,"activeCount":97},[],{"trials":255,"activeCount":97},[],{"trials":257,"activeCount":97},[],{"trials":259,"activeCount":139,"soonestReadout":59},[260],{"nctId":57,"briefTitle":58,"status":118,"phases":261,"primaryCompletion":59,"completion":237,"start":238,"enrollment":239,"conditions":262,"interventions":263},[89],[241,242,243],[60,245],{"trials":265,"activeCount":97},[],{"trials":267,"activeCount":97},[],{"intervention":269,"totalTrials":32,"cells":270},"Carboplatin",{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":309,"PHASE4":311,"NA":313},{"trials":272,"activeCount":97},[],{"trials":274,"activeCount":97},[],{"trials":276,"activeCount":139,"soonestReadout":83},[277,285,298],{"nctId":81,"briefTitle":82,"status":118,"phases":278,"primaryCompletion":83,"completion":279,"start":280,"enrollment":197,"conditions":281,"interventions":282},[88],"2031-08-28","2023-11-16",[24],[84,269,283,284],"Paclitaxel","Selinexor",{"nctId":286,"briefTitle":287,"status":109,"phases":288,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":295},"NCT00654836","Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer",[88],"2012-02","2015-09","2007-10",32,[294],"Breast Cancer",[296,269,297],"bevacizumab","ABI-007",{"nctId":299,"briefTitle":300,"status":109,"phases":301,"completion":302,"start":303,"conditions":304,"interventions":305},"NCT00002474","Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer",[88],"2005-10","1991-02",[24],[306,307,308],"carboplatin","cyclophosphamide","mitoxantrone hydrochloride",{"trials":310,"activeCount":97},[],{"trials":312,"activeCount":97},[],{"trials":314,"activeCount":97},[],{"intervention":84,"totalTrials":139,"cells":316},{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":327,"PHASE4":329,"NA":331},{"trials":318,"activeCount":97},[],{"trials":320,"activeCount":97},[],{"trials":322,"activeCount":139,"soonestReadout":83},[323],{"nctId":81,"briefTitle":82,"status":118,"phases":324,"primaryCompletion":83,"completion":279,"start":280,"enrollment":197,"conditions":325,"interventions":326},[88],[24],[84,269,283,284],{"trials":328,"activeCount":97},[],{"trials":330,"activeCount":97},[],{"trials":332,"activeCount":97},[],{"intervention":283,"totalTrials":139,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":345,"PHASE4":347,"NA":349},{"trials":336,"activeCount":97},[],{"trials":338,"activeCount":97},[],{"trials":340,"activeCount":139,"soonestReadout":83},[341],{"nctId":81,"briefTitle":82,"status":118,"phases":342,"primaryCompletion":83,"completion":279,"start":280,"enrollment":197,"conditions":343,"interventions":344},[88],[24],[84,269,283,284],{"trials":346,"activeCount":97},[],{"trials":348,"activeCount":97},[],{"trials":350,"activeCount":97},[],{"intervention":284,"totalTrials":139,"cells":352},{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":363,"PHASE4":365,"NA":367},{"trials":354,"activeCount":97},[],{"trials":356,"activeCount":97},[],{"trials":358,"activeCount":139,"soonestReadout":83},[359],{"nctId":81,"briefTitle":82,"status":118,"phases":360,"primaryCompletion":83,"completion":279,"start":280,"enrollment":197,"conditions":361,"interventions":362},[88],[24],[84,269,283,284],{"trials":364,"activeCount":97},[],{"trials":366,"activeCount":97},[],{"trials":368,"activeCount":97},[],{"intervention":45,"totalTrials":139,"cells":370},{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":372,"activeCount":97},[],{"trials":374,"activeCount":97},[],{"trials":376,"activeCount":139,"soonestReadout":44},[377],{"nctId":42,"briefTitle":43,"status":118,"phases":378,"primaryCompletion":44,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":384},[88],"2026-11-01","2023-03-07",100,[383],"Shingles",[45],{"trials":386,"activeCount":97},[],{"trials":388,"activeCount":97},[],{"trials":390,"activeCount":97},[],{"intervention":307,"totalTrials":27,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":410,"PHASE3":446,"PHASE4":448,"NA":450},{"trials":394,"activeCount":97},[],{"trials":396,"activeCount":139,"soonestReadout":39},[397],{"nctId":37,"briefTitle":38,"status":398,"phases":399,"primaryCompletion":39,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":407},"ACTIVE_NOT_RECRUITING",[87],"2034-12-31","2019-12-31",24,[404,405,406],"B-Cell Acute Lymphoblastic Leukemia, Adult","B-cell Lymphoma Refractory","B-cell Lymphoma Recurrent",[40,408,409],"Cyclophosphamide","CD19-CD34 CAR transduced T cells",{"trials":411,"activeCount":97},[412,426,442],{"nctId":413,"briefTitle":414,"status":109,"phases":415,"completion":416,"start":417,"conditions":418,"interventions":420},"NCT00004905","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia",[88],"2004-09","1999-10",[419],"Leukemia",[421,422,307,423,424,425],"filgrastim","recombinant interferon alfa","cytarabine","etoposide","idarubicin",{"nctId":427,"briefTitle":428,"status":429,"phases":430,"primaryCompletion":431,"completion":431,"start":432,"enrollment":22,"conditions":433,"interventions":439},"NCT03088709","Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide","TERMINATED",[88],"2022-01-31","2017-01-18",[434,435,436,437,438],"Acute Myeloid Leukemia","Acute Lymphocytic Leukemia","Myelodysplastic Syndrome","Non-hodgkin Lymphoma","Chronic Lymphocytic Leukemia",[408,440,441],"Tacrolimus","Mycophenolate mofetil",{"nctId":299,"briefTitle":300,"status":109,"phases":443,"completion":302,"start":303,"conditions":444,"interventions":445},[88],[24],[306,307,308],{"trials":447,"activeCount":97},[],{"trials":449,"activeCount":97},[],{"trials":451,"activeCount":97},[],{"intervention":40,"totalTrials":139,"cells":453},{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":462,"PHASE3":464,"PHASE4":466,"NA":468},{"trials":455,"activeCount":97},[],{"trials":457,"activeCount":139,"soonestReadout":39},[458],{"nctId":37,"briefTitle":38,"status":398,"phases":459,"primaryCompletion":39,"completion":400,"start":401,"enrollment":402,"conditions":460,"interventions":461},[87],[404,405,406],[40,408,409],{"trials":463,"activeCount":97},[],{"trials":465,"activeCount":97},[],{"trials":467,"activeCount":97},[],{"trials":469,"activeCount":97},[],{"intervention":409,"totalTrials":139,"cells":471},{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":473,"activeCount":97},[],{"trials":475,"activeCount":139,"soonestReadout":39},[476],{"nctId":37,"briefTitle":38,"status":398,"phases":477,"primaryCompletion":39,"completion":400,"start":401,"enrollment":402,"conditions":478,"interventions":479},[87],[404,405,406],[40,408,409],{"trials":481,"activeCount":97},[],{"trials":483,"activeCount":97},[],{"trials":485,"activeCount":97},[],{"trials":487,"activeCount":97},[],{"intervention":75,"totalTrials":139,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":501,"PHASE3":503,"PHASE4":505,"NA":507},{"trials":491,"activeCount":97},[],{"trials":493,"activeCount":139,"soonestReadout":74},[494],{"nctId":72,"briefTitle":73,"status":118,"phases":495,"primaryCompletion":74,"completion":74,"start":496,"enrollment":497,"conditions":498,"interventions":500},[87],"2015-02",18,[499],"Melanoma",[75],{"trials":502,"activeCount":97},[],{"trials":504,"activeCount":97},[],{"trials":506,"activeCount":97},[],{"trials":508,"activeCount":97},[],{"intervention":79,"totalTrials":139,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":524,"PHASE3":526,"PHASE4":528,"NA":530},{"trials":512,"activeCount":97},[],{"trials":514,"activeCount":139,"soonestReadout":74},[515],{"nctId":77,"briefTitle":78,"status":398,"phases":516,"primaryCompletion":74,"completion":74,"start":517,"enrollment":518,"conditions":519,"interventions":520},[87],"2012-07",14,[499],[79,521,522,523],"Dose 2","Dose 3","Dose 4",{"trials":525,"activeCount":97},[],{"trials":527,"activeCount":97},[],{"trials":529,"activeCount":97},[],{"trials":531,"activeCount":97},[],{"intervention":521,"totalTrials":139,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":542,"PHASE3":544,"PHASE4":546,"NA":548},{"trials":535,"activeCount":97},[],{"trials":537,"activeCount":139,"soonestReadout":74},[538],{"nctId":77,"briefTitle":78,"status":398,"phases":539,"primaryCompletion":74,"completion":74,"start":517,"enrollment":518,"conditions":540,"interventions":541},[87],[499],[79,521,522,523],{"trials":543,"activeCount":97},[],{"trials":545,"activeCount":97},[],{"trials":547,"activeCount":97},[],{"trials":549,"activeCount":97},[],{"intervention":522,"totalTrials":139,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":560,"PHASE3":562,"PHASE4":564,"NA":566},{"trials":553,"activeCount":97},[],{"trials":555,"activeCount":139,"soonestReadout":74},[556],{"nctId":77,"briefTitle":78,"status":398,"phases":557,"primaryCompletion":74,"completion":74,"start":517,"enrollment":518,"conditions":558,"interventions":559},[87],[499],[79,521,522,523],{"trials":561,"activeCount":97},[],{"trials":563,"activeCount":97},[],{"trials":565,"activeCount":97},[],{"trials":567,"activeCount":97},[],{"intervention":523,"totalTrials":139,"cells":569},{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":578,"PHASE3":580,"PHASE4":582,"NA":584},{"trials":571,"activeCount":97},[],{"trials":573,"activeCount":139,"soonestReadout":74},[574],{"nctId":77,"briefTitle":78,"status":398,"phases":575,"primaryCompletion":74,"completion":74,"start":517,"enrollment":518,"conditions":576,"interventions":577},[87],[499],[79,521,522,523],{"trials":579,"activeCount":97},[],{"trials":581,"activeCount":97},[],{"trials":583,"activeCount":97},[],{"trials":585,"activeCount":97},[],{"intervention":587,"totalTrials":588,"cells":589},"Solifenacin",2,{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":605,"PHASE4":607,"NA":618},{"trials":591,"activeCount":97},[],{"trials":593,"activeCount":97},[],{"trials":595,"activeCount":97},[596],{"nctId":597,"briefTitle":598,"status":109,"phases":599,"primaryCompletion":600,"completion":601,"start":517,"enrollment":602,"conditions":603,"interventions":604},"NCT01642277","Bacterial Genomic Sequencing in Overactive Bladder",[88],"2014-07","2014-08",134,[21],[587],{"trials":606,"activeCount":97},[],{"trials":608,"activeCount":97},[609],{"nctId":610,"briefTitle":611,"status":109,"phases":612,"primaryCompletion":613,"completion":613,"start":614,"enrollment":7,"conditions":615,"interventions":617},"NCT01559389","Incontinence & Intimate Partners: Assessing the Contribution of Treatment",[90],"2017-06-29","2012-03-09",[616],"Urge Urinary Incontinence",[587],{"trials":619,"activeCount":97},[],{"intervention":138,"totalTrials":588,"cells":621},{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":642,"NA":648},{"trials":623,"activeCount":97},[],{"trials":625,"activeCount":97},[],{"trials":627,"activeCount":97},[],{"trials":629,"activeCount":97},[630],{"nctId":631,"briefTitle":632,"status":130,"phases":633,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":640},"NCT02489019","Fentanyl Effect on Blood Pressure in Elderly Patients After Induction of General Anesthesia",[88,89],"2020-07","2022-12","2018-02-19",105,[639],"Hypotension",[138,641],"Fentanyl",{"trials":643,"activeCount":97},[644],{"nctId":128,"briefTitle":129,"status":130,"phases":645,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":646,"interventions":647},[90],[136],[70,138],{"trials":649,"activeCount":97},[],{"intervention":651,"totalTrials":139,"cells":652},"Quetiapine-XR",{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":659,"PHASE4":661,"NA":673},{"trials":654,"activeCount":97},[],{"trials":656,"activeCount":97},[],{"trials":658,"activeCount":97},[],{"trials":660,"activeCount":97},[],{"trials":662,"activeCount":97},[663],{"nctId":664,"briefTitle":665,"status":109,"phases":666,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":672},"NCT00951483","Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients",[90],"2011-10","2009-07",91,[34,671],"Anxiety",[651],{"trials":674,"activeCount":97},[],{"intervention":676,"totalTrials":139,"cells":677},"Mirabegron",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":686,"NA":697},{"trials":679,"activeCount":97},[],{"trials":681,"activeCount":97},[],{"trials":683,"activeCount":97},[],{"trials":685,"activeCount":97},[],{"trials":687,"activeCount":97},[688],{"nctId":689,"briefTitle":690,"status":109,"phases":691,"primaryCompletion":692,"completion":692,"start":693,"enrollment":694,"conditions":695,"interventions":696},"NCT02495389","Mirabegron and Urinary Urgency Incontinence",[90],"2019-01-29","2015-01-28",84,[21],[676],{"trials":698,"activeCount":97},[],{"intervention":700,"totalTrials":139,"cells":701},"Solifenacin Succinate",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":723},{"trials":703,"activeCount":97},[],{"trials":705,"activeCount":97},[],{"trials":707,"activeCount":97},[],{"trials":709,"activeCount":97},[],{"trials":711,"activeCount":97},[712],{"nctId":713,"briefTitle":714,"status":109,"phases":715,"primaryCompletion":716,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":722},"NCT00909428","Validation of a Real-time Urodynamic Measure of Urinary Urgency",[90],"2008-07","2009-02","2007-01",51,[721],"Overactive Bladder Syndrome",[700],{"trials":724,"activeCount":97},[],{"intervention":726,"totalTrials":139,"cells":727},"Melatonin",{"EARLY_PHASE1":728,"PHASE1":730,"PHASE2":732,"PHASE3":734,"PHASE4":736,"NA":748},{"trials":729,"activeCount":97},[],{"trials":731,"activeCount":97},[],{"trials":733,"activeCount":97},[],{"trials":735,"activeCount":97},[],{"trials":737,"activeCount":97},[738],{"nctId":739,"briefTitle":740,"status":741,"phases":742,"primaryCompletion":743,"completion":743,"start":744,"enrollment":97,"conditions":745,"interventions":747},"NCT02903901","Melatonin for Prevention of Post- Operative Delirium Pilot Study Protocol","WITHDRAWN",[90],"2018-06","2015-06",[746],"Delirium",[726],{"trials":749,"activeCount":97},[],{"intervention":751,"totalTrials":139,"cells":752},"Misoprostol",{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":759,"PHASE4":761,"NA":773},{"trials":754,"activeCount":97},[],{"trials":756,"activeCount":97},[],{"trials":758,"activeCount":97},[],{"trials":760,"activeCount":97},[],{"trials":762,"activeCount":97},[763],{"nctId":764,"briefTitle":765,"status":429,"phases":766,"primaryCompletion":767,"completion":767,"start":768,"enrollment":769,"conditions":770,"interventions":772},"NCT00383942","Ripening Interventions: Prostaglandins vs EASI Catheter",[90],"2008-06-18","2006-08-31",80,[771],"Cesarean Section",[751],{"trials":774,"activeCount":97},[],{"intervention":776,"totalTrials":139,"cells":777},"Enoxaparin Sodium 150 MG\u002FML Prefilled Syringe",{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":786,"NA":799},{"trials":779,"activeCount":97},[],{"trials":781,"activeCount":97},[],{"trials":783,"activeCount":97},[],{"trials":785,"activeCount":97},[],{"trials":787,"activeCount":97},[788],{"nctId":789,"briefTitle":790,"status":741,"phases":791,"primaryCompletion":792,"completion":792,"start":793,"enrollment":97,"conditions":794,"interventions":797},"NCT03081169","Timing of VTE Prophylaxis in TBI",[90],"2019-08-12","2017-04-03",[795,796],"TBI (Traumatic Brain Injury)","VTE (Venous Thromboembolism)",[776,798],"Heparin",{"trials":800,"activeCount":97},[],{"intervention":798,"totalTrials":139,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":809,"PHASE4":811,"NA":817},{"trials":804,"activeCount":97},[],{"trials":806,"activeCount":97},[],{"trials":808,"activeCount":97},[],{"trials":810,"activeCount":97},[],{"trials":812,"activeCount":97},[813],{"nctId":789,"briefTitle":790,"status":741,"phases":814,"primaryCompletion":792,"completion":792,"start":793,"enrollment":97,"conditions":815,"interventions":816},[90],[795,796],[776,798],{"trials":818,"activeCount":97},[],{"intervention":820,"totalTrials":139,"cells":821},"Escitalopram",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":828,"PHASE4":830,"NA":843},{"trials":823,"activeCount":97},[],{"trials":825,"activeCount":97},[],{"trials":827,"activeCount":97},[],{"trials":829,"activeCount":97},[],{"trials":831,"activeCount":97},[832],{"nctId":833,"briefTitle":834,"status":109,"phases":835,"primaryCompletion":836,"completion":837,"start":838,"enrollment":381,"conditions":839,"interventions":841},"NCT01479829","Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression",[90],"2017-12-28","2018-01-24","2011-03-23",[840],"Bipolar Depression",[820,842],"Celecoxib",{"trials":844,"activeCount":97},[],{"intervention":842,"totalTrials":139,"cells":846},{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":851,"PHASE3":853,"PHASE4":855,"NA":861},{"trials":848,"activeCount":97},[],{"trials":850,"activeCount":97},[],{"trials":852,"activeCount":97},[],{"trials":854,"activeCount":97},[],{"trials":856,"activeCount":97},[857],{"nctId":833,"briefTitle":834,"status":109,"phases":858,"primaryCompletion":836,"completion":837,"start":838,"enrollment":381,"conditions":859,"interventions":860},[90],[840],[820,842],{"trials":862,"activeCount":97},[],{"intervention":864,"totalTrials":139,"cells":865},"Conversion from IR Tacrolimus to XR Tacrolimus",{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":872,"PHASE4":874,"NA":887},{"trials":867,"activeCount":97},[],{"trials":869,"activeCount":97},[],{"trials":871,"activeCount":97},[],{"trials":873,"activeCount":97},[],{"trials":875,"activeCount":97},[876],{"nctId":877,"briefTitle":878,"status":130,"phases":879,"primaryCompletion":880,"completion":880,"start":881,"enrollment":882,"conditions":883,"interventions":886},"NCT04917718","Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacrolimus",[90],"2024-12-31","2021-08-16",42,[884,885],"Chronic Kidney Diseases","Heart Transplant",[864],{"trials":888,"activeCount":97},[],{"intervention":890,"totalTrials":139,"cells":891},"Intraperitoneal Ropivacaine",{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":898,"PHASE4":900,"NA":912},{"trials":893,"activeCount":97},[],{"trials":895,"activeCount":97},[],{"trials":897,"activeCount":97},[],{"trials":899,"activeCount":97},[],{"trials":901,"activeCount":97},[902],{"nctId":903,"briefTitle":904,"status":109,"phases":905,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":909,"interventions":910},"NCT01480089","Surgical Pain Control With Ropivacaine by Atomized Delivery",[90],"2013-02","2011-11",56,[29],[890,911],"Atomized Intraperitoneal Saline",{"trials":913,"activeCount":97},[],{"intervention":911,"totalTrials":139,"cells":915},{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":922,"PHASE4":924,"NA":930},{"trials":917,"activeCount":97},[],{"trials":919,"activeCount":97},[],{"trials":921,"activeCount":97},[],{"trials":923,"activeCount":97},[],{"trials":925,"activeCount":97},[926],{"nctId":903,"briefTitle":904,"status":109,"phases":927,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":928,"interventions":929},[90],[29],[890,911],{"trials":931,"activeCount":97},[],{"intervention":933,"totalTrials":139,"cells":934},"Bupivacaine",{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":941,"PHASE4":943,"NA":954},{"trials":936,"activeCount":97},[],{"trials":938,"activeCount":97},[],{"trials":940,"activeCount":97},[],{"trials":942,"activeCount":97},[],{"trials":944,"activeCount":97},[945],{"nctId":946,"briefTitle":947,"status":429,"phases":948,"primaryCompletion":949,"completion":949,"start":950,"enrollment":588,"conditions":951,"interventions":953},"NCT02951884","Intra-articular Local Anesthetic Injection and Hematoma Aspiration",[90],"2018-05-03","2016-06-15",[952],"Tibial Fractures",[933],{"trials":955,"activeCount":97},[],{"intervention":957,"totalTrials":139,"cells":958},"Standard PO",{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":965,"PHASE4":967,"NA":982},{"trials":960,"activeCount":97},[],{"trials":962,"activeCount":97},[],{"trials":964,"activeCount":97},[],{"trials":966,"activeCount":97},[],{"trials":968,"activeCount":97},[969],{"nctId":970,"briefTitle":971,"status":109,"phases":972,"primaryCompletion":973,"completion":974,"start":975,"enrollment":976,"conditions":977,"interventions":980},"NCT00781768","Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea",[90],"2008-10","2010-07","2003-08",181,[978,979],"Nausea","Vomiting",[957,981],"Aprepitant (MK-869) + Standard PO",{"trials":983,"activeCount":97},[],{"intervention":981,"totalTrials":139,"cells":985},{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":992,"PHASE4":994,"NA":1000},{"trials":987,"activeCount":97},[],{"trials":989,"activeCount":97},[],{"trials":991,"activeCount":97},[],{"trials":993,"activeCount":97},[],{"trials":995,"activeCount":97},[996],{"nctId":970,"briefTitle":971,"status":109,"phases":997,"primaryCompletion":973,"completion":974,"start":975,"enrollment":976,"conditions":998,"interventions":999},[90],[978,979],[957,981],{"trials":1001,"activeCount":97},[],{"intervention":1003,"totalTrials":139,"cells":1004},"Belladonna and opioid suppository",{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1009,"PHASE3":1011,"PHASE4":1013,"NA":1024},{"trials":1006,"activeCount":97},[],{"trials":1008,"activeCount":97},[],{"trials":1010,"activeCount":97},[],{"trials":1012,"activeCount":97},[],{"trials":1014,"activeCount":97},[1015],{"nctId":1016,"briefTitle":1017,"status":109,"phases":1018,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":381,"conditions":1021,"interventions":1022},"NCT01271855","Assessing Maternal Post-partum Pain With Suppositories",[90],"2011-09-29","2009-07-22",[29],[1003,1023],"Glycerin Suppository",{"trials":1025,"activeCount":97},[],{"intervention":1023,"totalTrials":139,"cells":1027},{"EARLY_PHASE1":1028,"PHASE1":1030,"PHASE2":1032,"PHASE3":1034,"PHASE4":1036,"NA":1042},{"trials":1029,"activeCount":97},[],{"trials":1031,"activeCount":97},[],{"trials":1033,"activeCount":97},[],{"trials":1035,"activeCount":97},[],{"trials":1037,"activeCount":97},[1038],{"nctId":1016,"briefTitle":1017,"status":109,"phases":1039,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":381,"conditions":1040,"interventions":1041},[90],[29],[1003,1023],{"trials":1043,"activeCount":97},[],{"intervention":1045,"totalTrials":139,"cells":1046},"Rocuronium",{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1053,"PHASE4":1055,"NA":1071},{"trials":1048,"activeCount":97},[],{"trials":1050,"activeCount":97},[],{"trials":1052,"activeCount":97},[],{"trials":1054,"activeCount":97},[],{"trials":1056,"activeCount":97},[1057],{"nctId":1058,"briefTitle":1059,"status":741,"phases":1060,"primaryCompletion":1061,"completion":132,"start":1062,"enrollment":97,"conditions":1063,"interventions":1068},"NCT03226080","GA\u002FSpinal vs. GA\u002FSpinal\u002FNMB for Operative Repair of Hip Fracture",[90],"2019-08","2017-07-19",[1064,1065,1066,1067],"Hip Fractures","Anesthesia, Spinal","Anesthesia, General","Neuromuscular Blockade",[1045,1069,1070],"Sugammadex","Normal saline",{"trials":1072,"activeCount":97},[],{"intervention":1069,"totalTrials":139,"cells":1074},{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1081,"PHASE4":1083,"NA":1089},{"trials":1076,"activeCount":97},[],{"trials":1078,"activeCount":97},[],{"trials":1080,"activeCount":97},[],{"trials":1082,"activeCount":97},[],{"trials":1084,"activeCount":97},[1085],{"nctId":1058,"briefTitle":1059,"status":741,"phases":1086,"primaryCompletion":1061,"completion":132,"start":1062,"enrollment":97,"conditions":1087,"interventions":1088},[90],[1064,1065,1066,1067],[1045,1069,1070],{"trials":1090,"activeCount":97},[],{"intervention":1070,"totalTrials":139,"cells":1092},{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1099,"PHASE4":1101,"NA":1107},{"trials":1094,"activeCount":97},[],{"trials":1096,"activeCount":97},[],{"trials":1098,"activeCount":97},[],{"trials":1100,"activeCount":97},[],{"trials":1102,"activeCount":97},[1103],{"nctId":1058,"briefTitle":1059,"status":741,"phases":1104,"primaryCompletion":1061,"completion":132,"start":1062,"enrollment":97,"conditions":1105,"interventions":1106},[90],[1064,1065,1066,1067],[1045,1069,1070],{"trials":1108,"activeCount":97},[],{"intervention":1110,"totalTrials":139,"cells":1111},"Oxytocin",{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1118,"PHASE4":1120,"NA":1136},{"trials":1113,"activeCount":97},[],{"trials":1115,"activeCount":97},[],{"trials":1117,"activeCount":97},[],{"trials":1119,"activeCount":97},[],{"trials":1121,"activeCount":97},[1122],{"nctId":1123,"briefTitle":1124,"status":429,"phases":1125,"primaryCompletion":1126,"completion":1126,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1135},"NCT03246919","Ideal Time of Oxytocin Infusion During Cesarean Section",[90],"2020-02-24","2017-09-13",68,[1130,1131,1132,1133,1134],"Blood Loss, Surgical","Postpartum Hemorrhage","Bleed Pregnancy","Pregnancy Related","Cesarean Section Complications",[1110],{"trials":1137,"activeCount":97},[],{"intervention":1139,"totalTrials":139,"cells":1140},"MK-0752",{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1160},{"trials":1142,"activeCount":97},[],{"trials":1144,"activeCount":97},[],{"trials":1146,"activeCount":97},[],{"trials":1148,"activeCount":97},[],{"trials":1150,"activeCount":97},[1151],{"nctId":1152,"briefTitle":1153,"status":109,"phases":1154,"primaryCompletion":1155,"completion":1155,"start":1156,"enrollment":1157,"conditions":1158,"interventions":1159},"NCT00756717","Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer",[90],"2011-12-21","2008-02-14",22,[294],[1139],{"trials":1161,"activeCount":97},[],{"intervention":1163,"totalTrials":139,"cells":1164},"0.5 units\u002Fkg daily insulin",{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1171,"PHASE4":1173,"NA":1187},{"trials":1166,"activeCount":97},[],{"trials":1168,"activeCount":97},[],{"trials":1170,"activeCount":97},[],{"trials":1172,"activeCount":97},[],{"trials":1174,"activeCount":97},[1175],{"nctId":1176,"briefTitle":1177,"status":109,"phases":1178,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1185},"NCT00911625","Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency",[90],"2011-06-30","2009-01-21",114,[1183,1184],"Type 2 Diabetes","Renal Insufficiency",[1163,1186],"0.25 units\u002Fkg daily insulin",{"trials":1188,"activeCount":97},[],{"intervention":1186,"totalTrials":139,"cells":1190},{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1197,"PHASE4":1199,"NA":1205},{"trials":1192,"activeCount":97},[],{"trials":1194,"activeCount":97},[],{"trials":1196,"activeCount":97},[],{"trials":1198,"activeCount":97},[],{"trials":1200,"activeCount":97},[1201],{"nctId":1176,"briefTitle":1177,"status":109,"phases":1202,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":1203,"interventions":1204},[90],[1183,1184],[1163,1186],{"trials":1206,"activeCount":97},[],{"intervention":1208,"totalTrials":139,"cells":1209},"hydroxyurea",{"EARLY_PHASE1":1210,"PHASE1":1212,"PHASE2":1214,"PHASE3":1216,"PHASE4":1218,"NA":1231},{"trials":1211,"activeCount":97},[],{"trials":1213,"activeCount":97},[],{"trials":1215,"activeCount":97},[],{"trials":1217,"activeCount":97},[],{"trials":1219,"activeCount":97},[1220],{"nctId":1221,"briefTitle":1222,"status":109,"phases":1223,"primaryCompletion":1224,"completion":635,"start":1225,"enrollment":1226,"conditions":1227,"interventions":1230},"NCT02149537","Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy\u002FSafety of Hydroxyurea Treatment",[90],"2017-09","2014-12",53,[1228,1229],"Sickle Cell Disease","Sickle Cell Anemia",[1208],{"trials":1232,"activeCount":97},[],{"intervention":1234,"totalTrials":139,"cells":1235},"Gadoterate",{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1240,"PHASE3":1242,"PHASE4":1244,"NA":1255},{"trials":1237,"activeCount":97},[],{"trials":1239,"activeCount":97},[],{"trials":1241,"activeCount":97},[],{"trials":1243,"activeCount":97},[],{"trials":1245,"activeCount":97},[1246],{"nctId":1247,"briefTitle":1248,"status":429,"phases":1249,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":134,"conditions":1252,"interventions":1254},"NCT02382380","Evaluation of Gadoterate in Patients With Renal Dysfunction",[90],"2024-03-20","2014-11-05",[1253],"Renal Dysfunction",[1234],{"trials":1256,"activeCount":97},[],{"intervention":1258,"totalTrials":139,"cells":1259},"discontinue statin",{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1266,"PHASE4":1268,"NA":1281},{"trials":1261,"activeCount":97},[],{"trials":1263,"activeCount":97},[],{"trials":1265,"activeCount":97},[],{"trials":1267,"activeCount":97},[],{"trials":1269,"activeCount":97},[1270],{"nctId":1271,"briefTitle":1272,"status":130,"phases":1273,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1276,"conditions":1277,"interventions":1280},"NCT03663049","The Impact of Statin Holiday in Dialysis Patients Over 70 Years Old on Mental Function, Physical Function and Frailty",[90],"2021-05","2018-08-17",30,[1278,1279],"ESRD","Cardiovascular Diseases",[1258],{"trials":1282,"activeCount":97},[],{"intervention":1284,"totalTrials":139,"cells":1285},"topical Timolol",{"EARLY_PHASE1":1286,"PHASE1":1288,"PHASE2":1290,"PHASE3":1292,"PHASE4":1294,"NA":1304},{"trials":1287,"activeCount":97},[],{"trials":1289,"activeCount":97},[],{"trials":1291,"activeCount":97},[],{"trials":1293,"activeCount":97},[],{"trials":1295,"activeCount":97},[1296],{"nctId":1297,"briefTitle":1298,"status":741,"phases":1299,"primaryCompletion":517,"completion":517,"start":1300,"enrollment":97,"conditions":1301,"interventions":1303},"NCT01250457","Topical Timolol for the Treatment of Benign Vascular Periocular Lesions",[90],"2010-06",[1302],"Benign Vascular Periocular Lesions",[1284],{"trials":1305,"activeCount":97},[],{"intervention":1307,"totalTrials":139,"cells":1308},"phenazopyridine HCl",{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1315,"PHASE4":1317,"NA":1329},{"trials":1310,"activeCount":97},[],{"trials":1312,"activeCount":97},[],{"trials":1314,"activeCount":97},[],{"trials":1316,"activeCount":97},[],{"trials":1318,"activeCount":97},[1319],{"nctId":1320,"briefTitle":1321,"status":109,"phases":1322,"primaryCompletion":1323,"completion":1323,"start":1324,"enrollment":1325,"conditions":1326,"interventions":1328},"NCT00771173","CATHETER ANALGESIA TRIAL Phenazopyrdine vs. Placebo: a Randomized Controlled Trial",[90],"2010-01","2008-08",258,[1327],"Catheter-related Bladder Discomfort",[1307],{"trials":1330,"activeCount":97},[],{"intervention":1332,"totalTrials":139,"cells":1333},"Naloxone",{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1354},{"trials":1335,"activeCount":97},[],{"trials":1337,"activeCount":97},[],{"trials":1339,"activeCount":97},[],{"trials":1341,"activeCount":97},[],{"trials":1343,"activeCount":97},[1344],{"nctId":1345,"briefTitle":1346,"status":429,"phases":1347,"primaryCompletion":1348,"completion":1348,"start":1349,"enrollment":1226,"conditions":1350,"interventions":1353},"NCT03176316","The Use of Oral Naloxone to Prevent Post Spinal Fusion Ileus",[90],"2020-02-20","2017-09-20",[1351,1352],"Ileus","Fusion of Spine",[1332],{"trials":1355,"activeCount":97},[],{"intervention":1357,"totalTrials":139,"cells":1358},"Estrogen Cream",{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1365,"PHASE4":1367,"NA":1381},{"trials":1360,"activeCount":97},[],{"trials":1362,"activeCount":97},[],{"trials":1364,"activeCount":97},[],{"trials":1366,"activeCount":97},[],{"trials":1368,"activeCount":97},[1369],{"nctId":1370,"briefTitle":1371,"status":109,"phases":1372,"primaryCompletion":1373,"completion":1374,"start":1375,"enrollment":1376,"conditions":1377,"interventions":1380},"NCT02835846","Investigation of the Effect of the Female Urinary Microbiome on Incontinence",[90],"2018-03","2018-05","2016-09",35,[21,1378,1379],"Incontinence","Nocturia",[1357],{"trials":1382,"activeCount":97},[],{"intervention":1384,"totalTrials":139,"cells":1385},"Levetiracetam",{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1394,"NA":1408},{"trials":1387,"activeCount":97},[],{"trials":1389,"activeCount":97},[],{"trials":1391,"activeCount":97},[],{"trials":1393,"activeCount":97},[],{"trials":1395,"activeCount":97},[1396],{"nctId":1397,"briefTitle":1398,"status":130,"phases":1399,"primaryCompletion":1400,"completion":1401,"start":1402,"enrollment":1403,"conditions":1404,"interventions":1407},"NCT03054285","Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?",[90],"2020-04-01","2021-04-01","2017-07-01",2300,[1405,1406],"Seizures","Traumatic Brain Injury",[1384],{"trials":1409,"activeCount":97},[],{"intervention":1411,"totalTrials":139,"cells":1412},"Ivabradine",{"EARLY_PHASE1":1413,"PHASE1":1415,"PHASE2":1417,"PHASE3":1419,"PHASE4":1421,"NA":1435},{"trials":1414,"activeCount":97},[],{"trials":1416,"activeCount":97},[],{"trials":1418,"activeCount":97},[],{"trials":1420,"activeCount":97},[],{"trials":1422,"activeCount":97},[1423],{"nctId":1424,"briefTitle":1425,"status":130,"phases":1426,"primaryCompletion":1427,"completion":1428,"start":1429,"enrollment":197,"conditions":1430,"interventions":1434},"NCT03387605","Effect of Ivabradine in Stage D HF\u002FCardiogenic Shock Patients on Dobutamine",[90],"2020-01","2020-06","2018-03-15",[1431,1432,1433],"Heart Failure","Cardiogenic Shock","Tachycardia",[1411],{"trials":1436,"activeCount":97},[],{"intervention":440,"totalTrials":588,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1449,"PHASE4":1462,"NA":1464},{"trials":1440,"activeCount":97},[],{"trials":1442,"activeCount":97},[],{"trials":1444,"activeCount":97},[1445],{"nctId":427,"briefTitle":428,"status":429,"phases":1446,"primaryCompletion":431,"completion":431,"start":432,"enrollment":22,"conditions":1447,"interventions":1448},[88],[434,435,436,437,438],[408,440,441],{"trials":1450,"activeCount":97},[1451],{"nctId":1452,"briefTitle":1453,"status":741,"phases":1454,"primaryCompletion":1455,"completion":1456,"start":1457,"enrollment":97,"conditions":1458,"interventions":1459},"NCT03066466","Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT",[89],"2020-02-28","2021-02-28","2019-12-10",[434,435,436],[1460,1461,440],"Atorvastatin","Methotrexate",{"trials":1463,"activeCount":97},[],{"trials":1465,"activeCount":97},[],{"intervention":641,"totalTrials":139,"cells":1467},{"EARLY_PHASE1":1468,"PHASE1":1470,"PHASE2":1472,"PHASE3":1474,"PHASE4":1480,"NA":1482},{"trials":1469,"activeCount":97},[],{"trials":1471,"activeCount":97},[],{"trials":1473,"activeCount":97},[],{"trials":1475,"activeCount":97},[1476],{"nctId":631,"briefTitle":632,"status":130,"phases":1477,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":1478,"interventions":1479},[88,89],[639],[138,641],{"trials":1481,"activeCount":97},[],{"trials":1483,"activeCount":97},[],{"intervention":1485,"totalTrials":139,"cells":1486},"Sublingual Fentanyl Spray",{"EARLY_PHASE1":1487,"PHASE1":1489,"PHASE2":1491,"PHASE3":1493,"PHASE4":1505,"NA":1507},{"trials":1488,"activeCount":97},[],{"trials":1490,"activeCount":97},[],{"trials":1492,"activeCount":97},[],{"trials":1494,"activeCount":97},[1495],{"nctId":1496,"briefTitle":1497,"status":429,"phases":1498,"primaryCompletion":1499,"completion":1500,"start":1501,"enrollment":588,"conditions":1502,"interventions":1504},"NCT02241486","Sublingual Fentanyl and Procedural Burn Pain",[89],"2014-09","2015-03","2013-09",[1503],"Burn Pain",[1485],{"trials":1506,"activeCount":97},[],{"trials":1508,"activeCount":97},[],{"intervention":1510,"totalTrials":139,"cells":1511},"Botulinum Toxin",{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1516,"PHASE3":1518,"PHASE4":1530,"NA":1532},{"trials":1513,"activeCount":97},[],{"trials":1515,"activeCount":97},[],{"trials":1517,"activeCount":97},[],{"trials":1519,"activeCount":97},[1520],{"nctId":1521,"briefTitle":1522,"status":109,"phases":1523,"primaryCompletion":1524,"completion":1524,"start":1525,"enrollment":1526,"conditions":1527,"interventions":1529},"NCT01586819","Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A",[89],"2013-05","2011-09",26,[1528],"Wrinkles",[1510],{"trials":1531,"activeCount":97},[],{"trials":1533,"activeCount":97},[],{"intervention":1535,"totalTrials":139,"cells":1536},"Interleukin-2",{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1555,"NA":1557},{"trials":1538,"activeCount":97},[],{"trials":1540,"activeCount":97},[],{"trials":1542,"activeCount":97},[],{"trials":1544,"activeCount":97},[1545],{"nctId":1546,"briefTitle":1547,"status":109,"phases":1548,"primaryCompletion":1549,"completion":1549,"start":1550,"enrollment":1551,"conditions":1552,"interventions":1554},"NCT00003126","Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer",[89],"2002-08","1997-06",69,[1553],"Kidney Cancer",[1535],{"trials":1556,"activeCount":97},[],{"trials":1558,"activeCount":97},[],{"intervention":1560,"totalTrials":139,"cells":1561},"Adductor Canal Block",{"EARLY_PHASE1":1562,"PHASE1":1564,"PHASE2":1566,"PHASE3":1568,"PHASE4":1580,"NA":1582},{"trials":1563,"activeCount":97},[],{"trials":1565,"activeCount":97},[],{"trials":1567,"activeCount":97},[],{"trials":1569,"activeCount":97},[1570],{"nctId":1571,"briefTitle":1572,"status":130,"phases":1573,"primaryCompletion":1574,"completion":1574,"start":1575,"enrollment":381,"conditions":1576,"interventions":1578},"NCT05004506","Intra-articular Analgesia Versus Adductor Canal Block for Arthroscopic Knee Surgery",[89],"2022-12-31","2016-04-20",[1577],"Post-Operative Pain, Chronic",[1560,1579],"Intra-articular",{"trials":1581,"activeCount":97},[],{"trials":1583,"activeCount":97},[],{"intervention":1579,"totalTrials":139,"cells":1585},{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1592,"PHASE4":1598,"NA":1600},{"trials":1587,"activeCount":97},[],{"trials":1589,"activeCount":97},[],{"trials":1591,"activeCount":97},[],{"trials":1593,"activeCount":97},[1594],{"nctId":1571,"briefTitle":1572,"status":130,"phases":1595,"primaryCompletion":1574,"completion":1574,"start":1575,"enrollment":381,"conditions":1596,"interventions":1597},[89],[1577],[1560,1579],{"trials":1599,"activeCount":97},[],{"trials":1601,"activeCount":97},[],{"intervention":1460,"totalTrials":139,"cells":1603},{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1610,"PHASE4":1616,"NA":1618},{"trials":1605,"activeCount":97},[],{"trials":1607,"activeCount":97},[],{"trials":1609,"activeCount":97},[],{"trials":1611,"activeCount":97},[1612],{"nctId":1452,"briefTitle":1453,"status":741,"phases":1613,"primaryCompletion":1455,"completion":1456,"start":1457,"enrollment":97,"conditions":1614,"interventions":1615},[89],[434,435,436],[1460,1461,440],{"trials":1617,"activeCount":97},[],{"trials":1619,"activeCount":97},[],{"intervention":1461,"totalTrials":139,"cells":1621},{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1628,"PHASE4":1634,"NA":1636},{"trials":1623,"activeCount":97},[],{"trials":1625,"activeCount":97},[],{"trials":1627,"activeCount":97},[],{"trials":1629,"activeCount":97},[1630],{"nctId":1452,"briefTitle":1453,"status":741,"phases":1631,"primaryCompletion":1455,"completion":1456,"start":1457,"enrollment":97,"conditions":1632,"interventions":1633},[89],[434,435,436],[1460,1461,440],{"trials":1635,"activeCount":97},[],{"trials":1637,"activeCount":97},[],{"intervention":1639,"totalTrials":32,"cells":1640},"Cholecalciferol",{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1678,"PHASE4":1680,"NA":1682},{"trials":1642,"activeCount":97},[],{"trials":1644,"activeCount":97},[],{"trials":1646,"activeCount":97},[1647,1657,1666],{"nctId":1648,"briefTitle":1649,"status":109,"phases":1650,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":22,"conditions":1653,"interventions":1656},"NCT03070483","Blood Pressure in Blacks and Calcium (BBC) and Vitamin D Study",[88],"2018-11-01","2018-03-25",[1654,1655],"Hypertension","Vitamin D Deficiency",[1639],{"nctId":1658,"briefTitle":1659,"status":429,"phases":1660,"primaryCompletion":1661,"completion":1661,"start":1662,"enrollment":908,"conditions":1663,"interventions":1665},"NCT02416193","Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)",[88],"2018-07-12","2015-09-23",[18,1664],"Executive Dysfunction",[1639,1639],{"nctId":1667,"briefTitle":1668,"status":109,"phases":1669,"primaryCompletion":1670,"completion":1671,"start":496,"enrollment":1672,"conditions":1673,"interventions":1677},"NCT02186015","Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)",[88],"2017-03-08","2017-11-09",43,[1674,1675,1676],"Adult Women","Metastatic Breast Cancer","Estrogen Receptor Positive",[1639],{"trials":1679,"activeCount":97},[],{"trials":1681,"activeCount":97},[],{"trials":1683,"activeCount":97},[],{"intervention":1685,"totalTrials":139,"cells":1686},"Bendamustine",{"EARLY_PHASE1":1687,"PHASE1":1689,"PHASE2":1691,"PHASE3":1702,"PHASE4":1704,"NA":1706},{"trials":1688,"activeCount":97},[],{"trials":1690,"activeCount":97},[],{"trials":1692,"activeCount":97},[1693],{"nctId":1694,"briefTitle":1695,"status":429,"phases":1696,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":32,"conditions":1699,"interventions":1701},"NCT01484626","Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma",[87,88],"2014-06-18","2011-05-05",[1700],"Multiple Myeloma",[1685],{"trials":1703,"activeCount":97},[],{"trials":1705,"activeCount":97},[],{"trials":1707,"activeCount":97},[],{"intervention":1709,"totalTrials":139,"cells":1710},"RICE",{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1715,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1712,"activeCount":97},[],{"trials":1714,"activeCount":97},[],{"trials":1716,"activeCount":97},[1717],{"nctId":1718,"briefTitle":1719,"status":741,"phases":1720,"primaryCompletion":1721,"completion":1721,"start":716,"enrollment":97,"conditions":1722,"interventions":1724},"NCT00836173","Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[88],"2012-05",[1723],"Diffuse Large B-cell Lymphoma",[1709,1725],"GaRD Treatment",{"trials":1727,"activeCount":97},[],{"trials":1729,"activeCount":97},[],{"trials":1731,"activeCount":97},[],{"intervention":1725,"totalTrials":139,"cells":1733},{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1735,"activeCount":97},[],{"trials":1737,"activeCount":97},[],{"trials":1739,"activeCount":97},[1740],{"nctId":1718,"briefTitle":1719,"status":741,"phases":1741,"primaryCompletion":1721,"completion":1721,"start":716,"enrollment":97,"conditions":1742,"interventions":1743},[88],[1723],[1709,1725],{"trials":1745,"activeCount":97},[],{"trials":1747,"activeCount":97},[],{"trials":1749,"activeCount":97},[],{"intervention":1751,"totalTrials":139,"cells":1752},"Pazopanib plus Paclitaxel",{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1768,"PHASE4":1770,"NA":1772},{"trials":1754,"activeCount":97},[],{"trials":1756,"activeCount":97},[],{"trials":1758,"activeCount":97},[1759],{"nctId":1760,"briefTitle":1761,"status":741,"phases":1762,"primaryCompletion":1763,"completion":1763,"start":1764,"enrollment":97,"conditions":1765,"interventions":1767},"NCT01179269","Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer",[88],"2012-10","2010-03",[1766],"Non-small Cell Lung Cancer",[1751],{"trials":1769,"activeCount":97},[],{"trials":1771,"activeCount":97},[],{"trials":1773,"activeCount":97},[],{"intervention":421,"totalTrials":139,"cells":1775},{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1780,"PHASE3":1786,"PHASE4":1788,"NA":1790},{"trials":1777,"activeCount":97},[],{"trials":1779,"activeCount":97},[],{"trials":1781,"activeCount":97},[1782],{"nctId":413,"briefTitle":414,"status":109,"phases":1783,"completion":416,"start":417,"conditions":1784,"interventions":1785},[88],[419],[421,422,307,423,424,425],{"trials":1787,"activeCount":97},[],{"trials":1789,"activeCount":97},[],{"trials":1791,"activeCount":97},[],{"intervention":422,"totalTrials":139,"cells":1793},{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1798,"PHASE3":1804,"PHASE4":1806,"NA":1808},{"trials":1795,"activeCount":97},[],{"trials":1797,"activeCount":97},[],{"trials":1799,"activeCount":97},[1800],{"nctId":413,"briefTitle":414,"status":109,"phases":1801,"completion":416,"start":417,"conditions":1802,"interventions":1803},[88],[419],[421,422,307,423,424,425],{"trials":1805,"activeCount":97},[],{"trials":1807,"activeCount":97},[],{"trials":1809,"activeCount":97},[],{"intervention":423,"totalTrials":139,"cells":1811},{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1816,"PHASE3":1822,"PHASE4":1824,"NA":1826},{"trials":1813,"activeCount":97},[],{"trials":1815,"activeCount":97},[],{"trials":1817,"activeCount":97},[1818],{"nctId":413,"briefTitle":414,"status":109,"phases":1819,"completion":416,"start":417,"conditions":1820,"interventions":1821},[88],[419],[421,422,307,423,424,425],{"trials":1823,"activeCount":97},[],{"trials":1825,"activeCount":97},[],{"trials":1827,"activeCount":97},[],{"intervention":424,"totalTrials":139,"cells":1829},{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1840,"PHASE4":1842,"NA":1844},{"trials":1831,"activeCount":97},[],{"trials":1833,"activeCount":97},[],{"trials":1835,"activeCount":97},[1836],{"nctId":413,"briefTitle":414,"status":109,"phases":1837,"completion":416,"start":417,"conditions":1838,"interventions":1839},[88],[419],[421,422,307,423,424,425],{"trials":1841,"activeCount":97},[],{"trials":1843,"activeCount":97},[],{"trials":1845,"activeCount":97},[],{"intervention":425,"totalTrials":139,"cells":1847},{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1858,"PHASE4":1860,"NA":1862},{"trials":1849,"activeCount":97},[],{"trials":1851,"activeCount":97},[],{"trials":1853,"activeCount":97},[1854],{"nctId":413,"briefTitle":414,"status":109,"phases":1855,"completion":416,"start":417,"conditions":1856,"interventions":1857},[88],[419],[421,422,307,423,424,425],{"trials":1859,"activeCount":97},[],{"trials":1861,"activeCount":97},[],{"trials":1863,"activeCount":97},[],{"intervention":1865,"totalTrials":139,"cells":1866},"Carboplatin and Paclitaxel",{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1871,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1868,"activeCount":97},[],{"trials":1870,"activeCount":97},[],{"trials":1872,"activeCount":97},[1873],{"nctId":1874,"briefTitle":1875,"status":130,"phases":1876,"primaryCompletion":880,"completion":880,"start":1877,"enrollment":402,"conditions":1878,"interventions":1880},"NCT03935256","Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer",[88],"2019-03-05",[1879],"Endometrial Cancer",[1865],{"trials":1882,"activeCount":97},[],{"trials":1884,"activeCount":97},[],{"trials":1886,"activeCount":97},[],{"intervention":1888,"totalTrials":139,"cells":1889},"Sodium thiosulfate",{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1891,"activeCount":97},[],{"trials":1893,"activeCount":97},[],{"trials":1895,"activeCount":97},[1896],{"nctId":1897,"briefTitle":1898,"status":741,"phases":1899,"primaryCompletion":1501,"completion":1501,"start":1501,"enrollment":97,"conditions":1900,"interventions":1902},"NCT01918904","A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis",[88],[1901],"Calcinosis Cutis",[1888],{"trials":1904,"activeCount":97},[],{"trials":1906,"activeCount":97},[],{"trials":1908,"activeCount":97},[],{"intervention":441,"totalTrials":139,"cells":1910},{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1921,"PHASE4":1923,"NA":1925},{"trials":1912,"activeCount":97},[],{"trials":1914,"activeCount":97},[],{"trials":1916,"activeCount":97},[1917],{"nctId":427,"briefTitle":428,"status":429,"phases":1918,"primaryCompletion":431,"completion":431,"start":432,"enrollment":22,"conditions":1919,"interventions":1920},[88],[434,435,436,437,438],[408,440,441],{"trials":1922,"activeCount":97},[],{"trials":1924,"activeCount":97},[],{"trials":1926,"activeCount":97},[],{"intervention":1928,"totalTrials":139,"cells":1929},"Intravenous Antibacterial Agent",{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1934,"PHASE3":1946,"PHASE4":1948,"NA":1950},{"trials":1931,"activeCount":97},[],{"trials":1933,"activeCount":97},[],{"trials":1935,"activeCount":97},[1936],{"nctId":1937,"briefTitle":1938,"status":429,"phases":1939,"primaryCompletion":1940,"completion":1940,"start":1941,"enrollment":1276,"conditions":1942,"interventions":1944},"NCT02168816","Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis",[88],"2017-02-02","2014-03-19",[1943],"Osteomyelitis",[1928,1945],"Oral Antibacterial Agent",{"trials":1947,"activeCount":97},[],{"trials":1949,"activeCount":97},[],{"trials":1951,"activeCount":97},[],{"intervention":1945,"totalTrials":139,"cells":1953},{"EARLY_PHASE1":1954,"PHASE1":1956,"PHASE2":1958,"PHASE3":1964,"PHASE4":1966,"NA":1968},{"trials":1955,"activeCount":97},[],{"trials":1957,"activeCount":97},[],{"trials":1959,"activeCount":97},[1960],{"nctId":1937,"briefTitle":1938,"status":429,"phases":1961,"primaryCompletion":1940,"completion":1940,"start":1941,"enrollment":1276,"conditions":1962,"interventions":1963},[88],[1943],[1928,1945],{"trials":1965,"activeCount":97},[],{"trials":1967,"activeCount":97},[],{"trials":1969,"activeCount":97},[],{"intervention":1971,"totalTrials":139,"cells":1972},"Remicaide",{"EARLY_PHASE1":1973,"PHASE1":1975,"PHASE2":1977,"PHASE3":1988,"PHASE4":1990,"NA":1992},{"trials":1974,"activeCount":97},[],{"trials":1976,"activeCount":97},[],{"trials":1978,"activeCount":97},[1979],{"nctId":1980,"briefTitle":1981,"status":741,"phases":1982,"primaryCompletion":1983,"completion":1983,"start":1984,"enrollment":97,"conditions":1985,"interventions":1987},"NCT00372723","Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)",[88],"2011-06","2006-07",[1986],"Toxic Epidermal Necrolysis",[1971],{"trials":1989,"activeCount":97},[],{"trials":1991,"activeCount":97},[],{"trials":1993,"activeCount":97},[],{"intervention":1995,"totalTrials":139,"cells":1996},"Minoxidil",{"EARLY_PHASE1":1997,"PHASE1":1999,"PHASE2":2001,"PHASE3":2011,"PHASE4":2013,"NA":2015},{"trials":1998,"activeCount":97},[],{"trials":2000,"activeCount":97},[],{"trials":2002,"activeCount":97},[2003],{"nctId":2004,"briefTitle":2005,"status":130,"phases":2006,"primaryCompletion":880,"completion":880,"start":2007,"enrollment":2008,"conditions":2009,"interventions":2010},"NCT05272462","Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer",[88],"2021-12-13",34,[24],[1995],{"trials":2012,"activeCount":97},[],{"trials":2014,"activeCount":97},[],{"trials":2016,"activeCount":97},[],{"intervention":2018,"totalTrials":139,"cells":2019},"Carfilzomib",{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2024,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2021,"activeCount":97},[],{"trials":2023,"activeCount":97},[],{"trials":2025,"activeCount":97},[2026],{"nctId":2027,"briefTitle":2028,"status":130,"phases":2029,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":2033,"conditions":2034,"interventions":2035},"NCT03795597","Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)",[87,88],"2022-11-01","2023-11-01","2019-05-22",36,[1700],[2018,2036,2037],"Busulfan IV","Melphalan IV",{"trials":2039,"activeCount":97},[],{"trials":2041,"activeCount":97},[],{"trials":2043,"activeCount":97},[],{"intervention":2036,"totalTrials":139,"cells":2045},{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2056,"PHASE4":2058,"NA":2060},{"trials":2047,"activeCount":97},[],{"trials":2049,"activeCount":97},[],{"trials":2051,"activeCount":97},[2052],{"nctId":2027,"briefTitle":2028,"status":130,"phases":2053,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":2033,"conditions":2054,"interventions":2055},[87,88],[1700],[2018,2036,2037],{"trials":2057,"activeCount":97},[],{"trials":2059,"activeCount":97},[],{"trials":2061,"activeCount":97},[],{"intervention":2037,"totalTrials":139,"cells":2063},{"EARLY_PHASE1":2064,"PHASE1":2066,"PHASE2":2068,"PHASE3":2074,"PHASE4":2076,"NA":2078},{"trials":2065,"activeCount":97},[],{"trials":2067,"activeCount":97},[],{"trials":2069,"activeCount":97},[2070],{"nctId":2027,"briefTitle":2028,"status":130,"phases":2071,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":2033,"conditions":2072,"interventions":2073},[87,88],[1700],[2018,2036,2037],{"trials":2075,"activeCount":97},[],{"trials":2077,"activeCount":97},[],{"trials":2079,"activeCount":97},[],{"intervention":2081,"totalTrials":139,"cells":2082},"Ontak",{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2087,"PHASE3":2097,"PHASE4":2099,"NA":2101},{"trials":2084,"activeCount":97},[],{"trials":2086,"activeCount":97},[],{"trials":2088,"activeCount":97},[2089],{"nctId":2090,"briefTitle":2091,"status":429,"phases":2092,"primaryCompletion":2093,"completion":2093,"start":973,"enrollment":10,"conditions":2094,"interventions":2096},"NCT00726037","A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer",[88],"2012-01",[2095],"Metastatic Pancreatic Cancer",[2081],{"trials":2098,"activeCount":97},[],{"trials":2100,"activeCount":97},[],{"trials":2102,"activeCount":97},[],{"intervention":296,"totalTrials":139,"cells":2104},{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2115,"PHASE4":2117,"NA":2119},{"trials":2106,"activeCount":97},[],{"trials":2108,"activeCount":97},[],{"trials":2110,"activeCount":97},[2111],{"nctId":286,"briefTitle":287,"status":109,"phases":2112,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":2113,"interventions":2114},[88],[294],[296,269,297],{"trials":2116,"activeCount":97},[],{"trials":2118,"activeCount":97},[],{"trials":2120,"activeCount":97},[],{"intervention":297,"totalTrials":139,"cells":2122},{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2133,"PHASE4":2135,"NA":2137},{"trials":2124,"activeCount":97},[],{"trials":2126,"activeCount":97},[],{"trials":2128,"activeCount":97},[2129],{"nctId":286,"briefTitle":287,"status":109,"phases":2130,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":2131,"interventions":2132},[88],[294],[296,269,297],{"trials":2134,"activeCount":97},[],{"trials":2136,"activeCount":97},[],{"trials":2138,"activeCount":97},[],{"intervention":2140,"totalTrials":139,"cells":2141},"DC vaccination",{"EARLY_PHASE1":2142,"PHASE1":2144,"PHASE2":2146,"PHASE3":2155,"PHASE4":2157,"NA":2159},{"trials":2143,"activeCount":97},[],{"trials":2145,"activeCount":97},[],{"trials":2147,"activeCount":97},[2148],{"nctId":2149,"briefTitle":2150,"status":130,"phases":2151,"primaryCompletion":2152,"completion":2152,"start":973,"enrollment":2033,"conditions":2153,"interventions":2154},"NCT00703105","Ovarian Dendritic Cell Vaccine Trial",[88],"2021-07",[24],[2140],{"trials":2156,"activeCount":97},[],{"trials":2158,"activeCount":97},[],{"trials":2160,"activeCount":97},[],{"intervention":308,"totalTrials":139,"cells":2162},{"EARLY_PHASE1":2163,"PHASE1":2165,"PHASE2":2167,"PHASE3":2173,"PHASE4":2175,"NA":2177},{"trials":2164,"activeCount":97},[],{"trials":2166,"activeCount":97},[],{"trials":2168,"activeCount":97},[2169],{"nctId":299,"briefTitle":300,"status":109,"phases":2170,"completion":302,"start":303,"conditions":2171,"interventions":2172},[88],[24],[306,307,308],{"trials":2174,"activeCount":97},[],{"trials":2176,"activeCount":97},[],{"trials":2178,"activeCount":97},[],{"intervention":2180,"totalTrials":139,"cells":2181},"Corticosteroid",{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2196,"PHASE4":2198,"NA":2200},{"trials":2183,"activeCount":97},[],{"trials":2185,"activeCount":97},[],{"trials":2187,"activeCount":97},[2188],{"nctId":2189,"briefTitle":2190,"status":429,"phases":2191,"primaryCompletion":2192,"completion":2192,"start":2193,"enrollment":588,"conditions":2194,"interventions":2195},"NCT02044991","Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain",[88],"2017-02-22","2013-10-24",[31],[2180],{"trials":2197,"activeCount":97},[],{"trials":2199,"activeCount":97},[],{"trials":2201,"activeCount":97},[],{"intervention":2203,"totalTrials":139,"cells":2204},"Defibrotide",{"EARLY_PHASE1":2205,"PHASE1":2207,"PHASE2":2209,"PHASE3":2223,"PHASE4":2225,"NA":2227},{"trials":2206,"activeCount":97},[],{"trials":2208,"activeCount":97},[],{"trials":2210,"activeCount":97},[2211],{"nctId":2212,"briefTitle":2213,"status":130,"phases":2214,"primaryCompletion":2215,"completion":2216,"start":2217,"enrollment":402,"conditions":2218,"interventions":2222},"NCT04313036","5-day Defibrotide Treatment for Hepatic SOS\u002FVOD",[88],"2022-05-01","2022-08-01","2021-03-11",[2219,2220,2221],"Sinusoidal Obstruction Syndrome","Veno-occlusive Disease","Bone Marrow Transplant Complications",[2203],{"trials":2224,"activeCount":97},[],{"trials":2226,"activeCount":97},[],{"trials":2228,"activeCount":97},[],{"intervention":2230,"totalTrials":139,"cells":2231},"Temsirolimus",{"EARLY_PHASE1":2232,"PHASE1":2234,"PHASE2":2236,"PHASE3":2248,"PHASE4":2250,"NA":2252},{"trials":2233,"activeCount":97},[],{"trials":2235,"activeCount":97},[],{"trials":2237,"activeCount":97},[2238],{"nctId":2239,"briefTitle":2240,"status":429,"phases":2241,"primaryCompletion":2242,"completion":2243,"start":2244,"enrollment":518,"conditions":2245,"interventions":2247},"NCT00838955","Temsirolimus for Relapsed\u002FRefractory Hodgkin's Lymphoma",[88],"2016-10","2017-10","2009-01",[2246],"Hodgkin's Lymphoma",[2230],{"trials":2249,"activeCount":97},[],{"trials":2251,"activeCount":97},[],{"trials":2253,"activeCount":97},[],{"intervention":2255,"totalTrials":139,"cells":2256},"StemEx",{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2271,"PHASE4":2273,"NA":2275},{"trials":2258,"activeCount":97},[],{"trials":2260,"activeCount":97},[],{"trials":2262,"activeCount":97},[2263],{"nctId":2264,"briefTitle":2265,"status":109,"phases":2266,"primaryCompletion":2267,"completion":2267,"start":1323,"enrollment":497,"conditions":2268,"interventions":2270},"NCT01484470","Umbilical Cord Transplantation for the Elderly Population",[88],"2018-11-21",[2269],"Hematologic Malignancies",[2255],{"trials":2272,"activeCount":97},[],{"trials":2274,"activeCount":97},[],{"trials":2276,"activeCount":97},[],{"intervention":2278,"totalTrials":139,"cells":2279},"Vitamin D3",{"EARLY_PHASE1":2280,"PHASE1":2282,"PHASE2":2284,"PHASE3":2298,"PHASE4":2300,"NA":2302},{"trials":2281,"activeCount":97},[],{"trials":2283,"activeCount":97},[],{"trials":2285,"activeCount":97},[2286],{"nctId":2287,"briefTitle":2288,"status":109,"phases":2289,"primaryCompletion":2290,"completion":2291,"start":2292,"enrollment":2293,"conditions":2294,"interventions":2296},"NCT01904032","Sunshine 2 Study for Women With Diabetes",[88],"2017-11-11","2018-08-31","2013-11-21",265,[18,34,2295],"Quality of Life",[2278,2297],"Vitamin D3 comparator",{"trials":2299,"activeCount":97},[],{"trials":2301,"activeCount":97},[],{"trials":2303,"activeCount":97},[],{"intervention":2297,"totalTrials":139,"cells":2305},{"EARLY_PHASE1":2306,"PHASE1":2308,"PHASE2":2310,"PHASE3":2316,"PHASE4":2318,"NA":2320},{"trials":2307,"activeCount":97},[],{"trials":2309,"activeCount":97},[],{"trials":2311,"activeCount":97},[2312],{"nctId":2287,"briefTitle":2288,"status":109,"phases":2313,"primaryCompletion":2290,"completion":2291,"start":2292,"enrollment":2293,"conditions":2314,"interventions":2315},[88],[18,34,2295],[2278,2297],{"trials":2317,"activeCount":97},[],{"trials":2319,"activeCount":97},[],{"trials":2321,"activeCount":97},[],{"intervention":2323,"totalTrials":139,"cells":2324},"lidocaine-prilocaine cream",{"EARLY_PHASE1":2325,"PHASE1":2327,"PHASE2":2329,"PHASE3":2340,"PHASE4":2342,"NA":2344},{"trials":2326,"activeCount":97},[],{"trials":2328,"activeCount":97},[],{"trials":2330,"activeCount":97},[2331],{"nctId":2332,"briefTitle":2333,"status":109,"phases":2334,"primaryCompletion":2335,"completion":2335,"start":2336,"enrollment":2337,"conditions":2338,"interventions":2339},"NCT02380742","Topical Anesthetic Use In Pessary Management",[88],"2016-02","2015-07",54,[29],[2323],{"trials":2341,"activeCount":97},[],{"trials":2343,"activeCount":97},[],{"trials":2345,"activeCount":97},[],{"intervention":2347,"totalTrials":139,"cells":2348},"HDR Brachytherapy + EBRT + STAD",{"EARLY_PHASE1":2349,"PHASE1":2351,"PHASE2":2353,"PHASE3":2364,"PHASE4":2366,"NA":2368},{"trials":2350,"activeCount":97},[],{"trials":2352,"activeCount":97},[],{"trials":2354,"activeCount":97},[2355],{"nctId":2356,"briefTitle":2357,"status":429,"phases":2358,"primaryCompletion":2359,"completion":2359,"start":2360,"enrollment":32,"conditions":2361,"interventions":2363},"NCT03553602","HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer",[87,88],"2024-07-26","2017-12-20",[2362],"Prostate Cancer - Recurrent",[2347],{"trials":2365,"activeCount":97},[],{"trials":2367,"activeCount":97},[],{"trials":2369,"activeCount":97},[],{"intervention":2371,"totalTrials":139,"cells":2372},"Azacitidine",{"EARLY_PHASE1":2373,"PHASE1":2375,"PHASE2":2384,"PHASE3":2386,"PHASE4":2388,"NA":2390},{"trials":2374,"activeCount":97},[],{"trials":2376,"activeCount":97},[2377],{"nctId":2378,"briefTitle":2379,"status":741,"phases":2380,"primaryCompletion":2381,"completion":2381,"start":717,"enrollment":97,"conditions":2382,"interventions":2383},"NCT00842582","Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer",[87],"2011-03",[24],[2371,2371,2371],{"trials":2385,"activeCount":97},[],{"trials":2387,"activeCount":97},[],{"trials":2389,"activeCount":97},[],{"trials":2391,"activeCount":97},[],{"intervention":2393,"totalTrials":139,"cells":2394},"Group A-Paravertebral block",{"EARLY_PHASE1":2395,"PHASE1":2397,"PHASE2":2399,"PHASE3":2401,"PHASE4":2403,"NA":2405},{"trials":2396,"activeCount":97},[],{"trials":2398,"activeCount":97},[],{"trials":2400,"activeCount":97},[],{"trials":2402,"activeCount":97},[],{"trials":2404,"activeCount":97},[],{"trials":2406,"activeCount":97},[2407],{"nctId":2408,"briefTitle":2409,"status":130,"phases":2410,"primaryCompletion":132,"completion":2411,"start":2412,"enrollment":134,"conditions":2413,"interventions":2415},"NCT01480102","Paravertebral Block for Percutaneous Nephrolithotomy",[91],"2021-08","2011-08",[2414],"Post Operative Pain",[2393],{"intervention":2417,"totalTrials":139,"cells":2418},"CMP",{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2423,"PHASE3":2425,"PHASE4":2427,"NA":2429},{"trials":2420,"activeCount":97},[],{"trials":2422,"activeCount":97},[],{"trials":2424,"activeCount":97},[],{"trials":2426,"activeCount":97},[],{"trials":2428,"activeCount":97},[],{"trials":2430,"activeCount":97},[2431],{"nctId":2432,"briefTitle":2433,"status":130,"phases":2434,"primaryCompletion":1574,"completion":1574,"start":2435,"enrollment":197,"conditions":2436,"interventions":2438},"NCT04426058","CMP vs Fascia Iliaca Block",[91],"2020-06-06",[159,2437],"Hip Arthroplasty",[2417,2439],"Fascia Illica",{"intervention":2439,"totalTrials":139,"cells":2441},{"EARLY_PHASE1":2442,"PHASE1":2444,"PHASE2":2446,"PHASE3":2448,"PHASE4":2450,"NA":2452},{"trials":2443,"activeCount":97},[],{"trials":2445,"activeCount":97},[],{"trials":2447,"activeCount":97},[],{"trials":2449,"activeCount":97},[],{"trials":2451,"activeCount":97},[],{"trials":2453,"activeCount":97},[2454],{"nctId":2432,"briefTitle":2433,"status":130,"phases":2455,"primaryCompletion":1574,"completion":1574,"start":2435,"enrollment":197,"conditions":2456,"interventions":2457},[91],[159,2437],[2417,2439],{"intervention":2459,"totalTrials":139,"cells":2460},"conjugated estrogen",{"EARLY_PHASE1":2461,"PHASE1":2463,"PHASE2":2465,"PHASE3":2467,"PHASE4":2469,"NA":2471},{"trials":2462,"activeCount":97},[],{"trials":2464,"activeCount":97},[],{"trials":2466,"activeCount":97},[],{"trials":2468,"activeCount":97},[],{"trials":2470,"activeCount":97},[],{"trials":2472,"activeCount":97},[2473],{"nctId":2474,"briefTitle":2475,"status":109,"phases":2476,"primaryCompletion":2477,"completion":2478,"start":2479,"enrollment":2480,"conditions":2481,"interventions":2482},"NCT02524769","The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides",[91],"2016-11","2017-06","2015-12",27,[21],[2459]]